230
Views
8
CrossRef citations to date
0
Altmetric
Original Research

The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up

ORCID Icon, , ORCID Icon, &
Pages 213-217 | Published online: 07 Apr 2021

References

  • PerouCM, SørlieT, EisenMB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752. PMID: 10963602. doi:10.1038/3502109310963602
  • MittendorfEA, Chavez-MacGregorM, VilaJ, et al. Bioscore: a staging system for breast cancer patients that reflects the prognostic significance of underlying tumor biology. Ann Surg Oncol. 2017;24(12):3502–3509. PMID: 28726077. doi:10.1245/s10434-017-6009-x28726077
  • BustreoS, Osella-AbateS, CassoniP, et al. Optimal Ki-67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157(2):363–371. doi:10.1007/s10549-016-3817-927155668
  • GoldhirschA, WoodWC, CoatesAS, GelberRD, ThurlimannB, SennHJ. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–1747. PMID: 21709140. doi:10.1093/annonc/mdr30421709140
  • MikamiY, UenoT, YoshimuraK, et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 ring study. Cancer Sci. 2013;104(11):1539–1543. PMID: 23905924. doi:10.1111/cas.1224523905924
  • CoatesAS, WinerEP, GoldhirschA, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2015;26(8):1533–1546. PMID: 25939896. doi:10.1093/annonc/mdv22125939896
  • GerdesJ, SchwabU, LemkeH, SteinH. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31(1):13–20. doi:10.1002/ijc.29103101046339421
  • LeeLH, YangH, BigrasG. Current breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases. Int J Cancer. 1983;31(1):13–20. doi:10.1002/ijc.29103101046339421
  • DowsettM, NielsenTO, A’HernR, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki-67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103(22):1656–1664. doi:10.1093/jnci/djr39321960707
  • PolleyMY, LeungSC, McShaneLM, et al. An international Ki-67 reproducibility study. Mod Pathol. 2015;28(6):778–786. doi:10.1038/modpathol.2015.3825698062
  • PolleyMY, LeungSC, GaoD, et al. An international study to increase concordance in Ki-67 scoring. Mod Pathol. 2015;28(6):778–786. doi:10.1038/modpathol.2015.3825698062
  • GabrielNH, JamesLC, CarlJD, et al.; American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.
  • SparanoJA, GrayRJ, MakowerDF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121. doi:10.1056/NEJMoa180471029860917